These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22935938)

  • 21. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
    Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK
    J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia.
    Kiser TH; Burch JC; Klem PM; Hassell KL
    Pharmacotherapy; 2008 Sep; 28(9):1115-24. PubMed ID: 18752382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The management of heparin-induced thrombocytopenia.
    Keeling D; Davidson S; Watson H;
    Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study.
    Boyce SW; Bandyk DF; Bartholomew JR; Frame JN; Rice L
    Am J Ther; 2011 Jan; 18(1):14-22. PubMed ID: 21079512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
    Jeske WP; Walenga JM
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1171-80. PubMed ID: 12211410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin?
    Seybert AL; Coons JC; Zerumsky K
    Pharmacotherapy; 2006 Feb; 26(2):229-41. PubMed ID: 16466327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in parenteral direct thrombin inhibitor use in pediatric patients: analysis of a large administrative database.
    Moffett BS; Teruya J
    Arch Pathol Lab Med; 2014 Sep; 138(9):1229-32. PubMed ID: 25171706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Percutaneous interventions in patients with immune-mediated heparin-induced thrombocytopenia.
    Nikolsky E; Dangas GD
    Semin Thromb Hemost; 2004 Jun; 30(3):305-14. PubMed ID: 15282653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and effectiveness outcomes of an inpatient collaborative drug therapy management service for direct thrombin inhibitors.
    Cooper T; White CL; Taber D; Uber WE; Kokko H; Mazur J
    Am J Health Syst Pharm; 2012 Nov; 69(22):1993-8. PubMed ID: 23135566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and implementation of a comprehensive heparin-induced thrombocytopenia recognition and management protocol.
    Smythe MA; Mehta TP; Koerber JM; Forsyth LL; Sykes E; Corbets LR; Melendy SM; Parikh R
    Am J Health Syst Pharm; 2012 Feb; 69(3):241-8. PubMed ID: 22261947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?
    Seidel H; Kolde HJ
    Clin Appl Thromb Hemost; 2018 Mar; 24(2):287-294. PubMed ID: 28320219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis.
    Sun Z; Lan X; Li S; Zhao H; Tang Z; Xi Y
    Int J Hematol; 2017 Oct; 106(4):476-483. PubMed ID: 28600720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis.
    Frame JN; Rice L; Bartholomew JR; Whelton A
    Clin Ther; 2010 Apr; 32(4):626-36. PubMed ID: 20435232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
    Bartholomew JR; Pietrangeli CE; Hursting MJ
    Drugs Aging; 2007; 24(6):489-99. PubMed ID: 17571914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia.
    Tang IY; Cox DS; Patel K; Reddy BV; Nahlik L; Trevino S; Murray PT
    Ann Pharmacother; 2005 Feb; 39(2):231-6. PubMed ID: 15632219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia.
    Kondo LM; Wittkowsky AK; Wiggins BS
    Ann Pharmacother; 2001 Apr; 35(4):440-51. PubMed ID: 11302409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standardizing the management of heparin-induced thrombocytopenia.
    Fugate S; Chiappe J
    Am J Health Syst Pharm; 2008 Feb; 65(4):334-9. PubMed ID: 18238772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.
    Cuker A; Arepally GM; Chong BH; Cines DB; Greinacher A; Gruel Y; Linkins LA; Rodner SB; Selleng S; Warkentin TE; Wex A; Mustafa RA; Morgan RL; Santesso N
    Blood Adv; 2018 Nov; 2(22):3360-3392. PubMed ID: 30482768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management.
    Napolitano LM; Warkentin TE; Almahameed A; Nasraway SA
    Crit Care Med; 2006 Dec; 34(12):2898-911. PubMed ID: 17075368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.
    Lewis BE; Wallis DE; Berkowitz SD; Matthai WH; Fareed J; Walenga JM; Bartholomew J; Sham R; Lerner RG; Zeigler ZR; Rustagi PK; Jang IK; Rifkin SD; Moran J; Hursting MJ; Kelton JG;
    Circulation; 2001 Apr; 103(14):1838-43. PubMed ID: 11294800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.